The below is taken from Krushingit’s post on the CHM thread but thought it was relevant as it relates to pancreatic treatments. Relates to a company (Nasdaq) called Revolution Medicines which designs inhibitors for RAS proteins. Different mode of action but interesting data (MC over $7B). Hard to compare as it’s after a previous treatment but our molecule is already seemingly pushing out the SOC survival rates. DYOR of course!
The below is taken from Krushingit’s post on the CHM thread but...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
-0.005(2.08%) |
Mkt cap ! $91.57M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 23.0¢ | $766.6K | 3.262M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 179879 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 402089 | 6 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |